top of page
Executive Spotlights

Aiolos Bio Launches with $245M Series A Investment

San Francisco and London, October 24, 2023 (Business Wire) -- Aiolos Bio, Inc. officially launches as a clinical-stage biopharmaceutical company, committed to addressing unmet medical needs in respiratory and inflammatory conditions. The company secures an oversubscribed $245 million in Series A funding.

Read full article here.

Recent Posts

See All

Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr

Life Science Headlines
bottom of page